Purchase Order HHSN272201601133P

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $19,987.50 on August 24, 2020, for antibodies. Performance is located in San Diego, California with completion scheduled for September 23, 2020. This firm fixed-price acquisition carries no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $16,345.50 purchase order to Biointron Biological USA Inc. for antibody expression services. As a firm fixed price contract, Biointron will provide the requested antibody expression services to NIH/NIAID at Metuchen, New Jersey from September 19, 2023 through December 29, 2023. No subcontractors or set aside designations were indicated. NIAID conducts and...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Invivogen for $22,176.00 on July 9, 2020. Work is performed in San Diego, California. The order covers VACCIGRADE - 1MG VAC-2395-1 as a firm fixed-price purchase. The order completion date is August 7, 2020.</p>

The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,657.20 firm fixed-price purchase order to Ebioscience, Inc., a subsidiary of Affymetrix, Inc., for the supply of monoclonal antibodies, including shipping charges. The contract, which does not have a set-aside designation, was awarded on September 11, 2011, with a completion date of September 19, 2012. This standing order is likely part of NIAID's broader efforts to...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Life Technologies Corporation for biomaterial on August 11, 2015, with a ceiling value of $34,000.00. Performance takes place in Grand Island, New York. The order is firm fixed price with an ultimate completion date of September 30, 2016.</p>

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...

This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for 83 brilliant violet antibodies valued at $20,818.35, with an award date of December 31, 2019 and ultimate completion date of December 30, 2020. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized monoclonal antibody on June 27, 2018, with a ceiling value of $30,289.88 and firm fixed pricing. Performance is located in Piscataway, New Jersey, with an ultimate completion date of July 10, 2018. No small business set-aside was used.</p>